Not Yet RecruitingNot Applicable

Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis

Germany200 participantsStarted 2026-06-15

Plain-language summary

Cardiac amyloidosis is a progressive disorder caused by extracellular deposition of amyloid fibrils in the heart, leading to heart failure and impaired cardiac function. Early diagnosis and targeted therapies are essential to improve patient outcomes. This prospective, single-center study aims to longitudinally follow patients with suspected cardiac amyloidosis to characterize disease progression and assess treatment effects. Participants will undergo cardiac magnetic resonance imaging (resting and exercise stress MRI), magnetic resonance spectroscopy, cardiopulmonary exercise testing (spiroergometry) and blood testing at baseline and at 6, 12, and 24 months

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 18 years * Male and female patients undergoing clinically indicated diagnostic work-up for amyloidosis or with a previously confirmed diagnosis of cardiac amyloidosis prior to initiation of therapy * Presence of left ventricular wall thickness \> 12 mm on transthoracic echocardiography and at least one "red flag" suggestive of cardiac amyloidosis (according to ESC 2021 criteria) or an otherwise clinically established suspicion of amyloidosis * Written informed consent Exclusion Criteria: * Age \< 18 years * Contraindications to cardiac MRI (e.g., metallic foreign bodies, older-generation pacemakers, severe obesity, claustrophobia) * Lack of written informed consent for study participation * Inability to comply with the study procedures

What they're measuring

Changes in myocardial structural parameters

Timeframe: after 6 and 12 months

Changes in myocardial function

Timeframe: after 6 and 12 months

Changes in myocardial metabolism under therapy

Timeframe: after 6 and 12 months

Trial details

NCT IDNCT07577466

SponsorHeinrich-Heine University, Duesseldorf

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2029-12-31

Contact for this trial

Fabian Voß, MD

02118105187 ctu@med.uni-duesseldorf.de

View on ClinicalTrials.gov More Amyloidosis Cardiac trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.